menu
Orano Med Announces Appointment of Dr. Volker Wagner as Chief Medical Officer
Orano Med (Orano group subsidiary), a leading innovator in the field of Targeted Alpha Therapies Orano in oncology, is thrilled to announce the appointment of Dr. Volker Wagner MD PhD as its new Chief Medical Officer. Dr. Wagner brings a wealth of experience and expertise to the role, having previously served as Vice President and Head of Clinical Development Radiopharmaceuticals at Bayer.
In his previous position at Bayer, Dr. Wagner played a pivotal role in the development of Radium-223 (Xofigo®) and early Targeted Alpha Therapies. His extensive background includes over 20 years of dedicated service in oncology and the pharmaceutical industry, building and leading high-performance Clinical Development and Medical Affairs organizations, both in Europe and the USA. Dr. Wagner is board certified in Internal Medicine, Medical Oncology, and Hematology, showcasing a comprehensive skill set that aligns with the goals of Orano Med.
In his previous position at Bayer, Dr. Wagner played a pivotal role in the development of Radium-223 (Xofigo®) and early Targeted Alpha Therapies. His extensive background includes over 20 years of dedicated service in oncology and the pharmaceutical industry, building and leading high-performance Clinical Development and Medical Affairs organizations, both in Europe and the USA. Dr. Wagner is board certified in Internal Medicine, Medical Oncology, and Hematology, showcasing a comprehensive skill set that aligns with the goals of Orano Med.
Commenting on his new role, Dr. Wagner expressed his enthusiasm for joining Orano Med:
"I am very delighted to be part of Orano Med, a pioneering company at the forefront of Targeted Alpha Therapies in oncology. I look forward to contributing to the advancement of innovative and impactful treatments that can make a difference in the lives of cancer patients."
"I am very delighted to be part of Orano Med, a pioneering company at the forefront of Targeted Alpha Therapies in oncology. I look forward to contributing to the advancement of innovative and impactful treatments that can make a difference in the lives of cancer patients."
Julien Dodet, CEO of Orano Med, also shared his excitement about the appointment, stating,
"We are thrilled to welcome Dr. Wagner to the Orano Med team. His extensive experience and leadership in clinical development will undoubtedly strengthen our capabilities and contribute to the success of our mission."
"We are thrilled to welcome Dr. Wagner to the Orano Med team. His extensive experience and leadership in clinical development will undoubtedly strengthen our capabilities and contribute to the success of our mission."